Scarica l'app Stockscreener
16.98
9.76%
1.51
Dopo l'orario di chiusura:
16.85
-0.13
-0.77%
Precedente Chiudi:
$15.47
Aprire:
$15.58
Volume 24 ore:
2.04M
Relative Volume:
1.04
Capitalizzazione di mercato:
$827.66M
Reddito:
$15.84M
Utile/perdita netta:
$-308.48M
Rapporto P/E:
-4.3096
EPS:
-3.94
Flusso di cassa netto:
$-153.08M
1 W Prestazione:
+10.26%
1M Prestazione:
+197.89%
6M Prestazione:
+272.37%
1 anno Prestazione:
+172.33%
Intervallo 1D:
$15.35
$17.58
Intervallo di 1 settimana:
$14.68
$17.71
Portata 52W:
$3.73
$17.71
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
16.98 | 827.66M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
(QURE) Technical Pivots with Risk Controls - Stock Traders Daily
uniQure (NASDAQ:QURE) Trading Up 5.8% on Analyst Upgrade - MarketBeat
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - MSN
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
CSL and uniQure Win 2023 Prix Galien USA Award - GuruFocus.com
57,333 Shares in uniQure (NASDAQ:QURE) Purchased by Y Intercept Hong Kong Ltd - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024 - CGTLive™
uniQure price target raised to $32 from $12 at Stifel - Yahoo Finance
uniQure (NASDAQ:QURE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus - MarketBeat
uniQure (NASDAQ:QURE) Shares Acquired by Fmr LLC - MarketBeat
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.2% Higher Following Analyst Upgrade - MarketBeat
uniQure FY2024 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies - News & Insights
QURE (uniQure NV) Free Cash Flow : $-193.09 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wells Fargo & Company Upgrades uniQure (NASDAQ:QURE) to "Strong-Buy" - MarketBeat
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - MSN
Goldman maintains Neutral rating on uniQure shares, cites FDA review By Investing.com - Investing.com Nigeria
Goldman maintains Neutral rating on uniQure shares, cites FDA review - Investing.com
UniQure Stock Hits 52-Week High at $13.72 Amidst Modest Annual Growth - Investing.com Canada
uniQure (NASDAQ:QURE) Shares Sold by Verition Fund Management LLC - MarketBeat
Raymond James Upgrades uniQure N.V. (QURE) - MSN
uniQure (NASDAQ:QURE) Upgraded to Sell at StockNews.com - MarketBeat
UniQure Stock Hits 52-Week High at $13.72 Amidst Modest Annual Growth By Investing.com - Investing.com South Africa
UniQure: Accelerated Approval Plan With US FDA May Save Five Years - Citeline
uniQure CFO Christian Klemt sells $13,559 in stock By Investing.com - Investing.com Nigeria
Uniqure stock doubles as FDA points to a BLA in Huntington’s - BioWorld Online
uniQure CFO Christian Klemt sells $13,559 in stock - Investing.com
uniQure CEO Matthew Kapusta sells $26,079 in stock By Investing.com - Investing.com Nigeria
uniQure’s AMT-130: A Bold Step For Huntington’s, But Not Without Hurdles (NASDAQ:QURE) - Seeking Alpha
uniQure CEO Matthew Kapusta sells $26,079 in stock - Investing.com India
uniQure stock boosted by FDA alignment on accelerated approval for AMT-130 - Investing.com
UniQure doubles on alignment with FDA on development plan for gene therapy - XM
uniQure Soars 111% on FDA Approval - Wall Street Pit
Gene therapy developer's stock doubles after FDA grants accelerated approval - The Business Journals
Raymond James, Cantor bullish on uniQure following FDA update (NASDAQ:QURE) - Seeking Alpha
UniQure (QURE) Stock Soars Over 121% on FDA Approval Pathway - GuruFocus.com
uniQure soars as it aligns regulatory path for Huntington’s candidate AMT-130 - The Pharma Letter
uniQure stock rockets 90% on FDA update for AMT-130 (NASDAQ:QURE) - Seeking Alpha
UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment - Marketscreener.com
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday - Benzinga
uniQure shares surge on FDA accelerated approval pathway accord By Investing.com - Investing.com South Africa
uniQure aligns with FDA on Accelerated Approval for AMT-130 - Investing.com India
uniQure shares surge on FDA accelerated approval pathway accord - Investing.com India
uniQure aligns with FDA on Accelerated Approval for AMT-130 By Investing.com - Investing.com Canada
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease - The Manila Times
uniQure Announces Alignment with FDA on Key Elements of - GlobeNewswire
UniQure shares soar on chance of speedy approval for Huntington’s therapy - Yahoo Finance
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Dec 09 '24 |
Sale |
7.55 |
1,796 |
13,560 |
166,713 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):